Kornimate/medical-research-clean huggingface dataset:
breast and abdominal related morbidity of diep and siea flaps

Conditions: DIEP Flap Breast Reconstruction; SIEA Flap Breast Reconstruction

Summary: the deep inferior epigastric perforator flap (diep) is the current standard of care in breast reconstruction. the newer superficial inferior epigastric artery flap (siea) is felt to be an improvement as it does not damage the abdominal wall. the siea unfortunately has smaller vessels which put the flap at a higher risk of developing flap loss and fat necrosis. the uncertainty regarding the tradeoffs inherent in the choice of procedure has not been resolved. as such the investigators aim to perform a randomized single blinded trial to evaluate the abdominal and breast related morbidity associated with diep and siea flaps.

a blinded, randomized, prospective clinical trial is being performed involving manitoban women over 18 years undergoing unilateral or bilateral breast reconstruction. women were originally randomized 50/50 to either the diep or siea group. due to only about 60-70% of patients randomized to the siea group actually receiving the siea procedure, the weight of the randomization has now been changed to 70/30 (siea/diep) for the remainder of the study (approx. 40/110 recruited patients waiting for their or). objective isokinetic abdominal strength testing is being done pre-operatively and 3, 6 and 12 months post-operatively. a self-administered validated abdominal wall and breast outcome questionnaire (breast-q) is also given preoperatively and at 3 and 12 months postoperatively in . secondary outcomes measured include: fat necrosis, abdominal wound breakdown, flap loss and seroma rate. fat necrosis is detected using ultrasonography. abdominal wound breakdown is measured using calipers. seroma rates are tabulated and drainage volumes measured. statistical analyses include a combination of parametric and non-parametric tests.

Eligibility criteria:
inclusion criteria: * female subject older than 18 * with satisfactory abdominal tissue for diep and siea flap reconstruction * fluent in english exclusion criteria: * reconstruction planned using latissimus dorsi flap, gluteal artery perforator flap or tissue expansion * suffer from neurological back problems * suffer form inguinal hernias

Keywords: diep flap siea flap breast reconstruction objective isokinetic abdominal strength testing fat necrosis flap loss seroma rate abdominal wound breakdown breast-q abdominal wall outcome questionnaire
severe and transient hypoxemia during selective intra-arterial chemotherapy for retinoblastoma in children: evaluation of the right-sided heart function.

Conditions: Retinoblastoma

Summary: children having selective ophthalmic artery chemotherapy for retinoblastoma under general anaesthesia may experience troubles during the procedure. the troubles are transient, may be severe and include hypoxemia, hypotension and bradycardia. all children having such trouble always fully recovered without any sequelae or prolonged length of stay. the investigators suspect that these phenomenons are caused by transient pulmonary hypertension.the objective is to see whether transient pulmonary hypertension and right-sided heart failure is present during theses phenomenon by trans-thoracic echocardiography.


Eligibility criteria:
inclusion criteria: * retinoblastoma requiring selective ophthalmic artery chemotherapy under general anaesthesia exclusion criteria: * obesity * pre-existing significant heart or pulmonary disease.
emotion regulation as a moderator of two different treatments for children with odd

Conditions: Oppositional Defiant Disorder

Summary: the goal of this randomized controlled trial is to is to test emotion regulation as a moderator of two different treatments for children with oppositional defiant disorder (odd). the main question it aims to answer is whether treatment gains be increased when children with odd receive a treatment congruent with their emotion regulation skill problems. participants will be divided into two groups based on their response patterns; a high emotion dysregulation group and a low emotion dysregulation group. within each group, children will then be randomly assigned to either a behavioral parent training intervention or a child directed treatment involving problem solving and emotion regulation skills.

emotion regulation has been implicated in the development of odd. two types of treatment are commonly used for children with odd, behavioral parent training and child directed cognitive treatments. parent training focuses on increasing compliance and reducing defiant behaviour while the child directed treatments focus on increasing the child's problem solving skills and emotion regulation. the investigators will assess emotion regulation and emotional lability in children diagnosed with odd and divide them into two groups based on their response patterns; a high emotion dysregulation group and a low emotion dysregulation group. within each group, children will then be randomly assigned to either a behavioral parent training intervention or a child directed treatment involving problem solving and emotion regulation skills, which makes it possible to assess the effects of the different interventions for the two distinct groups. treatment effects will be assessed at pre- and post-treatment as well as at 6 and 18 month follow-up. comorbid conditions will be tested as moderators.

Eligibility criteria:
inclusion criteria: * diagnosed with oppositional defiant disorder * icelandic speaking (child and parent/guardian) exclusion criteria: * iq below 70 (full scale score)

Keywords: oppositional defiant disorder emotion regulation child psychopathology
activity and participation in vestibular disorders

Conditions: Vestibular Disorder

Summary: this study will examine whether impairments and personal factors are associated with activity and participation in people with vestibulopathy. data collection will occur prior to starting vestibular rehabilitation and after completing vestibular rehabilitation.

adults aged 18-years and older with symptomatic complaints of dizziness and/or imbalance and a medical diagnosis of unilateral vestibular hypofunction will be recruited at the time of their entry into vestibular rehabilitation. the investigators will analyze what factors (impairments and personal factors) are related to activity and participation in people with vestibular disorders and see if change in activity and participation is related to recovery from vestibulopathy.

Eligibility criteria:
inclusion criteria: - 18-years and older with symptomatic complaints of dizziness and/or imbalance and a medical diagnosis of unilateral vestibular hypofunction exclusion criteria: * 1. cognition \<18 on montreal cognitive assessment (moca) * 2. visual acuity worse than 20/40 with corrected lenses * 3. loss of protective distal sensation (defined as the inability to feel a 4.31 size monofilament on the plantar surface of the foot) * 4. inability to engage in community mobility

Keywords: vestibular rehabilitation activity and participation
evaluation of calcinosis in systemic sclerosis

Conditions: Systemic Sclerosis

Summary: systemic sclerosis is a rare pathology characterized by fibrosis and vascular lesion with skin, pulmonary, digestive and cardiac localisation. calcinosis cutis is commonly described, but its prevalence and appear few documented in literature. moreover, this studies used clinical observation to determine presence or absence of calcification, and rarely radiography, in particular for feet localisation. in the same way, skin calcification and organ injury association appear unclear. the aim of the study is firstly to determine prevalence of calcinosis cutis, with hand and feet radiography realisation in a cohort of systemic sclerosis patient. secondly, will be determine the correlation between calcinosis and organ injury.


Eligibility criteria:
inclusion criteria: * systemic sclerosis presenting acr-eular 2013 criteria * given their consent * titulary of health insurance exclusion criteria: * dermatomyositis overlap * pregnant or breastfeeding women * imprisoned person * refuse of consent

Keywords: systemic sclerosis calcinosis cutis
efficacy and safety of las41003 in the treatment of superficial infected eczema

Conditions: Eczema

Summary: the aim of the study is to determine the efficacy and safety of topical application of las41003 in comparison to las189962 and las189961 in the treatment of superinfected eczema.


Eligibility criteria:
inclusion criteria: * clinically diagnosed super-infected or impetiginized eczema exclusion criteria: * patients who have general signs of systemic infections like fever, malaise, lymphangitis or swollen lymph nodes and / or need systemic antibiotic treatment * patients who have a bacterial skin infection which, due to depth and severity, could not be appropriately treated with a topical antimicrobial or antiseptic medication * diagnose of the following disease: * known active tuberculosis or any history of past tuberculosis of skin * suspected or proven parasitic infection of the treatment site (e.g. scabies) * psoriasis * suspected or proven viral infection of skin (e.g. herpes) * localization of the superficial infected eczema: * palms of the hands * sole of a foot * face * have received any topical treatment with antibiotics, antimycotics, immunomodulators and corticosteroid preparations within the last 2 weeks before treatment with imp

Keywords: superficial infected eczema superinfected eczema
treatment in acute benign paroxysmal positional vertigo

Conditions: Benign Paroxysmal Positional Vertigo; Balance; Distorted; Vestibular Disorder; Dizziness

Summary: benign paroxysmal positional vertigo (bppv) is a vestibular disorder that manifests itself as a result of dizziness caused by the otoconia in the inner ear coming out of their places and circulating freely in the semicircular canals or by attaching to the cupula and sensitizing the cupula to head movements against gravity. the aim of the study is to compare the effectiveness of pharmacological treatment initiated by the physician and vestibular rehabilitation initiated by physiotherapist in patients with acute benign paroxysmal positional vertigo (bppv). thirty patients, aged 18-50 years, who applied to the bağcılar safa hospital, were included in the study. the patients were divided into two groups, 15 pharmacological control group and 15 vestibular rehabilitation group. 8 patients in the pharmacological control group were given the drug containing betahistine by the physician, and 7 patients received the drug containing additional dimenhydrinate to the betahistine. in the rehabilitation group, exercises including head and eye movements and maneuvering were performed according to the direction of the canal after the exercise, and the patients were given a home exercise program. treatment continued for 4 weeks. visual analogue scale (vas), dynamic visual acuity test, romberg, semitandem, tandem posture tests with a stopwatch, standing test on one leg with eyes open and closed, and unterberger tests were applied to patients before and after treatment.


Eligibility criteria:
inclusion criteria: * 18-50 years of age, * positive dix-hallpike test result, and * no spontaneous nystagmus. exclusion criteria: * patients with meniere's disease, vestibular neuritis, labyrinthitis, sudden sensory hearing loss, chronic otitis media, non-ambulatory patients, patients with vertigo due to central causes, and patients with cardiac complaints were excluded from the study. * in addition, patients with conditions contraindicated for canalith repositioning procedures (such as cervical spine stenosis, severe kyphoscoliosis, cervical radiculopathy, ankylosing spondylitis, severe lumbar dysfunction, and spinal injuries) were excluded from the vestibular rehabilitation group.

Keywords: benign paroxsymal positional vertigo balance pysiotherapy and rehabilitation canalith repositioning procedure pharmacological therapy dynamic visual acuity dizziness
collection of blood in studying metabolites in patients with prostate cancer

Conditions: Prostate Carcinoma

Summary: this pilot research trial utilizes the collection of blood in studying metabolites in patients with prostate cancer. metabolites are the small molecule products of cellular metabolism that are produced naturally in all living cells. collecting blood in order to study metabolites may help doctors monitor and treat prostate cancer more effectively.

primary objectives: i. develop blood sample collection and preparation procedures for reliable, meaningful metabolomic profiling of peripheral blood mononuclear cells (pbmcs) by liquid chromatography/quadruple-time of flight/mass spectrometry (lc/q-tof/ms) that can be implemented in a clinical setting. ii. optimize data analysis methods and software usage to create a metabolic profile for patients at the time of blood collection. iii. compare metabolite profiles of isolated pbmcs versus (vs.) other blood fractions (plasma, red blood cells \[rbcs\], and whole blood). iv. identify elements of the pbmc metabolite profile that may correlate to patient disease state. outline: patients undergo collection of blood for metabolic profiling via lc/q-tof/ms.

Eligibility criteria:
inclusion criteria: * all subjects will have histologically confirmed prostate cancer * provide written consent/authorization to participate in this study * have no signs or symptoms of active infection * exhibit a willingness to comply with the experimental procedures as outlined in this protocol
a study to determine the efficacy and safety of albiglutide as compared with liraglutide.

Conditions: Diabetes Mellitus, Type 2

Summary: this open-label study examines the efficacy and safety of albiglutide as compared with liraglutide in subjects with type 2 diabetes.

this randomized, open-label, multicenter, 2 parallel-group study evaluates the efficacy and safety of a weekly subcutaneously injected dose of albiglutide as compared with liraglutide. subjects with a historical diagnosis of type 2 diabetes mellitus and whose glycemia is inadequately controlled on their current regimen of metformin, thiazolidinedione, sulfonylurea, or any combination of these oral antidiabetics will be recruited into the study.

Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes mellitus and experiencing inadequate glycemic control on their current regimen of metformin, tzd, su, or any combination of these oral antidiabetic medications * bmi \>/=20kg/m2 and \</=45 kg/m2 * fasting c-peptide \>/=0.8 ng/ml (\>/=0.26 nmol/l) * hba1c between 7.0% and 10.0%, inclusive * female subjects of childbearing potential must be practicing adequate contraception. exclusion criteria: * history of cancer * history of treated diabetic gastroparesis * current biliary disease or history of pancreatitis * history of significant gi surgery * recent clinically significant cardiovascular and/or cerebrovascular disease * hypertension * history of human immunodeficiency virus infection * history of or current liver disease or acute symptomatic infection with hepatitis b or hepatitis c * history of alcohol or substance abuse * female subject is pregnant, lactating, or \<6 weeks postpartum * known allergy to any glp 1 analogue, liraglutide, other study medications' excipients, excipients of albiglutide, or baker's yeast * history of type 1 diabetes mellitus * contraindications (as per the prescribing information) for the use of either background or potential randomized study medications (e.g., liraglutide) * receipt of any investigational drug or liraglutide within the 30 days or 5 half lives, whichever is longer, before screening or a history of receipt of an investigational antidiabetic drug within the 3 months before randomization or receipt of albiglutide in previous studies * history or family history of thyroid disease

Keywords: gsk716155 liraglutide albiglutide open-label
a clinical trial on autologous nk cells combined with gd2 monoclonal antibody in the treatment of children with newly diagnosed high-risk or relapsed/refractory neuroblastoma

Conditions: Neuroblastoma; GD2 Antibody; Autologous NK Cell

Summary: this is a prospective, single-arm, open, single-center clinical trial to evaluate the safety and efficacy of autologous nk cells combined with chemotherapy and gd2 monoclonal antibody in the treatment of newly diagnosed high-risk or relapsed/refractory neuroblastoma in children. fifteen eligible subjects are planned to be included. the objective is to evaluate the safety and efficacy of autologous nk cells combined with gd2 monoclonal antibody in the treatment of children with newly diagnosed high-risk or relapsed/refractory neuroblastoma, which is expected to be safe and effective in improving pfs and dcr in children with refractory/recurrent neuroblastoma.


Eligibility criteria:
inclusion criteria: 1. age 1-18 years (including 18 years), gender not restricted; 2. diagnosed with high-risk neuroblastoma and meeting the following conditions: high-risk neuroblastoma has undergone standardized treatment including induction therapy and consolidation therapy according to cog, siopen or the expert consensus cccg-nb-2021, and has entered the maintenance stage; high-risk neuroblastoma has undergone induction therapy with cog chemotherapy combined with gd2 immunotherapy and has entered the maintenance stage; any recurrence of high-risk neuroblastoma after standardized treatment; or the disease is initially determined to be in a refractory state. 3. if it is relapsed/refractory neuroblastoma, there must be at least one measurable lesion according to recist 1.1 criteria; 4. normal major organ function, that is, meeting the following standards: (1) blood routine test: hemoglobin \>= 80 g/l; absolute neutrophil count (anc) \>=0.75×10\^9/l; platelet count \>= 75×10\^9/l; (2) blood biochemistry test: serum albumin \>=28 g/l; total bilirubin \ = 50%, and no severe arrhythmia; (5) no severe lung or kidney disease, no active pulmonary infection. indoor air oxygen saturation \>=92%; 5. expected survival time \>= 6 months; 6. after obtaining full informed consent from the patient and guardian, sign the informed consent form. exclusion criteria: 1. uncontrollable active infections, or expected to receive systemic anti-infection or immunosuppressive therapy during participation in this trial; 2. any toxic reactions caused by previous anti-tumor treatments have not recovered to grade 1 or below (ctcae 5.0 version) (hair loss is not restricted); 3. have a history of organ transplantation or are expected to undergo organ transplantation during the trial period; 4. highly allergic constitution; 5. hiv infection; 6. the researchers believe that there are other circumstances in which the subjects are not suitable to participate in this study.

Keywords: neuroblastoma gd2 antibody autologous nk cell
psychological and ethical support for hospital professionals during the covid-19 pandemic: suitability and post-crisis implications for the experience of all professionals

Conditions: Psychological Stress

Summary: sars-cov-2 has created an unprecedented health crisis, resulting in unprecedented mobilization of all hospital professionals. the massive influx of patients overwhelmed the human, therapeutic and material resources available, and teams were confronted with an unusually heavy workload in a highly stressful emergency context. these professionals were thus exposed to a risk of over-investment in a context of acute and repetitive stress over an indefinite period of time, combining a heavy workload, emotional challenges and specific ethical issues. these factors simultaneously affected the professional sphere but also the personal and family spheres (lockdown, risk of contamination). in this context, the mental health of hospital staff is considered to be more important than ever, as emphasized on numerous occasions by the director general of health and the french minister for health and solidarity. mental health involves the way in which individuals respond specifically to work-related suffering by developing individual and collective defensive strategies. thus, the question of the mental health of hospital professionals cannot be considered without taking into account the strategies implmented to combat stress, and the factors that contribute or not to the construction and stabilization of the work environment (collaboration, support).


Eligibility criteria:
inclusion criteria: all professionals working in hospitals professionals involved in the organization of psychological and ethical support may also be interviewed to provide the information necessary to describe and evaluate the support provided and how it changed over time. exclusion criteria: none
plasmatic catecholamines: randomized controlled trial comparing epidural versus combined spinal-epidural

Conditions: Fetal Bradycardia; Hypertonic Uterine; Catecholamines

Summary: combined spinal-epidural (cse) for labor analgesia has been associated with fetal bradycardia and uterine hypertonia, possibly due to asymmetric decrease in catecholamine levels, when compared with epidural analgesia (ep).

background: combined spinal-epidural technique for labor analgesia has been associated with fetal bradycardia and uterine hypertonia, when compared with epidural analgesia, possibly due to asymmetric decrease in catecholamine levels (epinephrine and norepinephrine) following neuraxial block. however, there are no studies comparing plasmatic catecholamine levels between those two techniques. this study aimed to compare spinal-epidural versus epidural regarding pre and post-analgesia catecholamine levels, uterine tone and fetal heart rate. methods: randomized clinical trial with 47 laboring patients divided in two groups. primary outcome was plasmatic catecholamine measurements before and after neuraxial block. secondary outcomes were fetal heart rate changes, uterine hypertonia, hypotension episodes, pain relief and fetal outcomes.

Eligibility criteria:
inclusion criteria: parturients aged over 18 years were included when they requested labor analgesia. the inclusion criteria were: patients between 37 and 42 gestational weeks, single pregnancy, in active labor (induced or spontaneous), requesting analgesia with 7 cm or less of cervical dilation. as it is a center that attends only high-risk pregnancies, asa ii or iii exclusion criteria: contraindications to interventions, either due to severe comorbidity or contraindication to neuraxial block; previous use of systemic opioids during labor, maternal amniotic infection or known fetal diseases

Keywords: analgesia fetal bradycardia hypertonic uterine